- Janux Therapeutics (JANX, Financial) initiates Phase 1b expansion studies for its prostate cancer treatment JANX007.
- Updated data shows improved median radiographic progression-free survival (rPFS) results supporting expansion studies.
- Additional data on JANX007 and JANX008 expected in the second half of 2025.
San Diego-based Janux Therapeutics, Inc. (JANX), a clinical-stage biopharmaceutical company, has commenced Phase 1b expansion studies with its drug candidate JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). These studies are part of the ongoing ENGAGER-PSMA-01 trial, which aims to assess the safety and efficacy of JANX007. The expansion will focus on taxane-naïve mCRPC patients and evaluate JANX007's efficacy at various doses, administered either weekly or biweekly.
The decision to advance to Phase 1b follows positive results from the Phase 1a dose escalation portion completed in December 2024. The updated data, as of April 21, 2025, reports a median radiographic progression-free survival (rPFS) of 7.5 months for all patients involved (n=16), with a higher median rPFS of 7.9 months for those treated at 6mg and 9mg doses (n=9). Additionally, the 6-month rPFS rates were 65% for all patients and rose to 78% in the higher dose group.
Janux Therapeutics plans to broaden its research efforts by initiating three other Phase 1b studies, which will explore JANX007 in combination therapies and further enhance the understanding of its efficacy in earlier stages of mCRPC. These efforts underline Janux's commitment to developing non-chemotherapeutic options for cancer patients. Furthermore, data from JANX007 and another candidate, JANX008, are anticipated to be disclosed later in 2025.
Janux's innovative platforms, TRACTr and TRACIr, are designed to create tumor-activated immunotherapies that aim to enhance patient safety while effectively targeting cancer cells. The company remains focused on expanding its pipeline to address various solid tumor types, leveraging its proprietary technology.
